rs1165196 — SLC17A1 SLC17A1 T269I (NPT1)

Missense variant in SLC17A1 (NPT1) encoding a Thr269Ile substitution; the G allele (Thr269) is a gain-of-function variant that enhances renal NPT1-mediated urate secretion and lowers gout risk, while the common A allele (Ile269) carries baseline NPT1 activity and higher gout susceptibility

See your personal result for SLC17A1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

SLC17A1 T269I — The NPT1 Urate Exporter Gain-of-Function Variant

The kidneys are the primary route of uric acid excretion, and their efficiency depends on a balance between transporters that reabsorb urate from the filtrate and those that secrete it into urine for elimination. On the apical (urine-facing) surface of the proximal tubule, NPT1 (sodium-dependent phosphate transport protein 1), encoded by SLC17A1, acts as a urate efflux transporter — pumping uric acid from tubular cells into the tubular lumen11 NPT1 (sodium-dependent phosphate transport protein 1), encoded by SLC17A1, acts as a urate efflux transporter — pumping uric acid from tubular cells into the tubular lumen. rs1165196 is a missense variant in SLC17A1 that directly changes the protein's amino acid at position 269 (Thr↔Ile), and this change has measurable consequences for how efficiently NPT1 exports urate from the kidney.

The Mechanism

The A allele at rs1165196 encodes isoleucine at position 269 (Ile269) — the common form of NPT1 in most global populations. The G allele encodes threonine at the same position (Thr269), and this substitution alters the transport kinetics of the protein. Functional studies using Xenopus oocyte expression systems showed that the Thr269 variant increases urate transport by raising the maximum transport rate (Vmax) without changing the substrate affinity (Km) or membrane expression level22 the Thr269 variant increases urate transport by raising the maximum transport rate (Vmax) without changing the substrate affinity (Km) or membrane expression level
Sakiyama et al. 2016: gain-of-function mechanism confirmed in NPT1 I269T (Thr269) variant. This means the Thr269 protein is intrinsically more active — each transporter molecule moves more urate per unit time — without the cell needing to produce more copies.

The net effect is a higher urate secretory rate in the proximal tubule, directly lowering the serum urate setpoint in Thr269 carriers. Carriers of the Ile269 form (A allele) have baseline NPT1 activity and correspondingly higher serum urate relative to Thr269 carriers.

The Evidence

The functional significance of rs1165196 was established in a study of 582 Japanese gout patients and controls: the Thr269 variant significantly decreased risk of renal underexcretion gout (OR 0.73, p=0.031), confirming that enhanced NPT1 urate export reduces the most common gout subtype33 the Thr269 variant significantly decreased risk of renal underexcretion gout (OR 0.73, p=0.031), confirming that enhanced NPT1 urate export reduces the most common gout subtype
Chiba et al. 2015, Arthritis & Rheumatology. Renal underexcretion gout accounts for approximately 80–90% of primary gout cases, making NPT1 function a clinically important determinant. An earlier study of 103 Japanese male gout patients found the coding-equivalent C allele (Thr269) protective against gout at OR 0.55 (p=0.0035)44 the coding-equivalent C allele (Thr269) protective against gout at OR 0.55 (p=0.0035)
Urano et al. 2010, Annals of the Rheumatic Diseases, with a significant gene-obesity interaction: the protective effect on serum uric acid was amplified in individuals with BMI ≥25.

The rs1165196 locus overlaps with the broader SLC17A1 GWAS signal for serum urate. The linked intronic variant rs1183201 reached genome-wide significance (p=3.0×10⁻¹⁴) in a meta-analysis of 28,141 Europeans, confirming that this chromosomal region materially influences the renal urate setpoint across populations.

The Thr269 allele (G on the plus strand) reaches its highest frequency in Europeans (~44%) and South Asians (~47%), while the Ile269 allele (A) is dominant in East Asian (~85%) and African (~89%) populations. This ancestry stratification helps explain why gout prevalence differs substantially across populations and is particularly relevant for interpreting genetic risk in multi-ancestry settings.

Practical Actions

For carriers of the AA genotype (Ile/Ile), NPT1 operates at baseline efficiency. Since approximately 80–90% of gout is driven by renal underexcretion rather than overproduction, reduced secretory capacity from this locus compounds with other urate transport variants to elevate the serum urate setpoint. Dietary purine management (limiting shellfish, organ meats, and fructose-sweetened beverages) reduces the substrate load the kidney must clear.

For AG heterozygotes, one NPT1 allele carries the gain-of-function Thr269 and the other the baseline Ile269, yielding intermediate urate secretory capacity. Periodic monitoring of serum uric acid is warranted, especially if other urate-raising variants are present.

Interactions

rs1165196 is in linkage disequilibrium (r² ≈ 0.8–0.9) with the intronic variant rs1183201 in the same gene, which has more direct GWAS association data for serum urate. Both variants capture the same biological signal — NPT1-mediated urate secretory capacity at the SLC17A1 locus. When both are genotyped, rs1165196 provides the mechanistic interpretation (gain-of-function protein change) while rs1183201 provides population-level effect size data.

The most clinically important interaction is with rs2231142 in ABCG2, the second major apical urate secretory transporter. ABCG2 Q141K (rs2231142 T allele) reduces ABCG2 transport activity by approximately 50%, and carriers of both SLC17A1 Ile269 (A allele) and ABCG2 Q141K have dual impairment of apical urate secretion — both major secretory routes compressed simultaneously. This compound effect is especially prevalent in East Asian populations and substantially elevates gout risk beyond either variant alone.

Nutrient Interactions

purine altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

GG High NPT1 Activity Beneficial

Gain-of-function NPT1 — enhanced renal urate secretion, lowest gout risk at this locus

You carry two copies of the G allele (Thr269) at rs1165196, encoding the gain-of-function form of NPT1 that exports urate more efficiently than the common Ile269 protein. Functional studies confirm this variant increases NPT1 transport capacity (higher Vmax) without changing its expression or substrate affinity. The GG genotype is found in approximately 17% of people globally and about 19% of Europeans. Your NPT1-mediated urate secretion operates at the highest functional level at this locus, supporting a lower serum urate setpoint and reduced risk of renal underexcretion gout compared to carriers of the A allele.

AG Intermediate NPT1 Activity Intermediate

One gain-of-function allele — moderately improved urate secretion, reduced gout risk

The codominant inheritance pattern means one NPT1 allele at a time operates in each tubular cell, with Thr269 providing gain-of-function transport kinetics alongside Ile269 baseline activity. This results in intermediate overall secretion rates. The Chiba 2015 study found that OR for renal underexcretion gout decreases with each Thr269 allele carried (0.73 per allele), so heterozygotes have an intermediate benefit compared to GG or AA homozygotes. The interaction with ABCG2 rs2231142 is most relevant for heterozygotes: if you also carry ABCG2 impairment variants, your combined secretory capacity may still be meaningfully reduced despite carrying one gain-of-function NPT1 allele.

AA Baseline NPT1 Activity High Risk

Common Ile269 genotype — baseline NPT1 urate secretion, highest relative gout risk at this locus

The AA genotype carries the Ile269 form of NPT1 on both chromosomes. Functional studies (Chiba 2015, Sakiyama 2016) confirm this as the baseline activity protein: without the Thr269 enhancement, each NPT1 molecule exports urate at the standard rate. The Urano 2010 study found the protective Thr269 allele (C on coding strand, G on plus strand) associated with OR 0.55 in gout patients, implying the Ile269 homozygous state carries roughly double the risk at this locus compared to Thr269 carriers. There was also a significant gene-BMI interaction: the relative disadvantage of the Ile269 genotype was amplified in individuals with BMI ≥25, likely because adiposity independently increases uric acid production, compounding the secretory limitation. In East Asian and African populations where Ile269 is dominant, the high prevalence of this genotype contributes to the elevated gout burden in these groups.